Showing: 1 - 3 of 3 RESULTS

Disc Medicine Expands Scientific Advisory Board with Leading Experts in Hepcidin Biology

CAMBRIDGE, Mass., Oct. 13, 2020 /PRNewswire/ — Disc Medicine, a company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced the appointment of Tomas Ganz, MD, PhD and Elizabeta Nemeth, PhD to its scientific advisory board, adding valuable expertise in hepcidin biology.

Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is advancing first-in-class therapies to transform the treatment of hematologic diseases. (PRNewsfoto/Disc Medicine)

“We are thrilled to welcome  Dr. Ganz and Dr. Nemeth to our Scientific Advisory Board, particularly at such an exciting time in a field that they helped pioneer,” said John Quisel, JD, PhD, Chief Executive Officer at Disc Medicine. “Together they were instrumental in characterizing the fundamental role of hepcidin in iron homeostasis, and I’m delighted to be working with them as we advance our hepcidin-targeted programs into the clinic.”

Dr. Ganz is a Distinguished Professor of Medicine and Pathology at the David Geffen School of Medicine at UCLA, where he studies the role of small peptide regulators in human physiology and disease and is credited for the discovery of the iron-regulatory hormone hepcidin. Dr. Ganz received his PhD in Applied Physics from Caltech and his MD from UCLA, joining UCLA as a faculty member in 1983 after having completed training in Internal Medicine and Pulmonary Medicine. In 2005 he received the Marcel Simon Prize of the International Bioiron Society for the discovery of hepcidin and in 2014 was honored by the E. Donnall Thomas Award from the American Society of Hematology for his research in iron homeostasis, including the discovery of the iron-regulatory hormone hepcidin and investigation of its roles in iron metabolism.

“It has been immensely gratifying to see the hepcidin story unfold as our understanding of hepcidin’s role across different diseases has grown,” said Tomas Ganz, MD PhD. “Disc has taken a compelling approach to targeting hepcidin with two programs guided by human genetic findings. I’m delighted to be a part of this vision, particularly as they look to enter the clinic with their first program next year.”

Dr. Nemeth is a Professor of Medicine at the David Geffen School of Medicine at UCLA, and Director of the UCLA Center for Iron Disorders. Dr. Nemeth received her PhD in Cell, Molecular and Neurosciences at the University of Hawaii and completed a postdoctoral fellowship studying the pathobiology of hepcidin at UCLA. During her tenure she has made major contributions to the understanding of iron homeostasis and its dysregulation in disease, such as characterizing the regulation of hepcidin production by inflammation and iron and elucidating the mechanism of action of hepcidin in regulating dietary iron absorption and release from stores. Dr. Nemeth also described the role of hepcidin in various iron disorders including hereditary hemochromatosis, iron-loading anemias and iron-restricted anemias. Dr. Nemeth was a standing member of the Molecular and Cellular Hematology Study Section of the National Institutes of Health, is President-Elect of the International BioIron Society, and an associate editor of the American Journal of Hematology. Dr. Ganz and Nemeth co-founded three biotechnology companies focused on hepcidin-targeted

Baker names 17-member coronavirus vaccine advisory group

A 17-member group of doctors, public health experts, lawmakers and community activists will guide Gov. Charlie Baker’s administration on how to distribute a coronavirus vaccine — once one is available — equitably, safely and efficiently.

There are currently 11 vaccine candidates in the last phase of clinical trials testing for safety and efficacy, according to the New York Times vaccine tracker. Massachusetts’ own Moderna is currently conducting some of its trials at Brigham & Women’s Hospital in Boston. Moderna and Pfizer are leading the pack, most likely to cross the finish line to a viable vaccine first, experts have said.

The advisory group held its first meeting last week and the governor’s office said its work will build on vaccine planning that has been underway since August.

Members are working closely with leaders from the Department of Public Health and adding to the commonwealth’s state-of-the-art Massachusetts Immunization Information System, which serves as the state’s vaccine registry, ordering and inventory mechanism. More than 3,000 provider sites currently report their data to this system. The DPH is adding 1,000 clinical sites to track the distribution of a COVID-19 vaccine, according to the governor’s office.

Members of the advisory committee include:

  • Dr. Paul Biddinger, chair of Mass General Brigham
  • Dr. Barry Bloom of Harvard T.H. Chan School of Public Health
  • Dr. Vincent Chiang of Boston Children’s Hospital
  • Michael Curry of Massachusetts League of Community Health Centers
  • Dr. Robert Finberg of University of Massachusetts Medical School
  • Sen. Cindy Friedman, chairperson of the Joint Committee on Health Care Financing
  • Dr. Marc Lipsitch of Harvard T.H. Chan School of Public Health
  • Rep. Ronald Mariano, House majority leader
  • Wanda McClain of Brigham and Women’s Hospital
  • Dr. Asif Merchant of Mass Medical Society
  • Mayor Daniel Rivera of Lawrence
  • Dr. John Rocchio of CVS Health
  • Dr. David Twitchell of Boston Medical Center
  • Rev. Liz Walker of Roxbury Presbyterian Church
  • Phoebe Walker of Franklin Regional Council of Governments
  • Dr. Simone Wildes of South Shore Hospital
  • Dr. Sharon Wright of Beth Israel Lahey Health

Source Article

EyeGuide Adds Six Sports Medicine, Neuroscience Experts to Scientific Advisory Board

EyeGuide Inc., a health technology and bioinformatics company revolutionizing the way brain health is monitored, has announced the expansion of its scientific advisory board with the additions of Dr. Anne Naclerio, Dr. Dhiren Naidu, Dr. Jon Patricios, Dr. Kathryn Schneider, Dr. Karen Sutton and Dr. Michael Turner. Each of these leading scientific experts brings specialized skills, knowledge and experience to help the EyeGuide team build a world-class advisory board.

“EyeGuide is doing important work to improve ocular-motor assessment of athletes with suspected brain injuries, to advance brain health, and to improve the wellness and performance of athletes of all ages. This is an exciting step forward for EyeGuide as the company now gains further support from an array of respected senior experts across the field of sports medicine and neuroscience,” said Dr. Ruben Echemendia, Chairperson of EyeGuide Scientific Advisory Board, which was established earlier this year. “I am eager to work together with this impressive team of advisers as well as collaborate on providing insight and guidance to EyeGuide so its products may help improve the lives of many people across the U.S. and around the world.”

The new members of EyeGuide’s Scientific Advisory Board include:

  • Dr. Anne Naclerio has spent the past 10 years working as chief of clinical operations for the Regional Health Command Atlantic, deputy surgeon for the U.S. Army in Europe, the command surgeon for the Army National Guard, and the chief of medical readiness and policy for the U.S. Army Surgeon General. Dr. Naclerio served in the Army for over 30 years and has earned numerous decorations including the Bronze Star, Purple Heart and the Legion of Merit. She also established and led the Women’s Health Taskforce to enable the services to better understand and meet the unique needs of female service members.

  • Dr. Dhiren Naidu is a tenured associate professor in the Division of Physical Medicine and Rehabilitation at the University of Alberta. He is also currently the head team physician for the National Hockey League’s Edmonton Oilers, the lead physician for the Canadian Football League’s Edmonton Eskimos, the head physician for the University of Alberta Golden Bears football team and a health physician for their varsity athletic program.

  • Dr. Jon Patricios is an associate professor in the Wits Faculty of Health Sciences and director of Wits Sport and Health (WiSH). He is also the current director of Waterfall Sports Orthopaedic Surgery in Johannesburg; founder and Director of Sports Concussion South Africa; sports concussion consultant to World Rugby; a board member of the international Concussion in Sports Group; and on the Scientific Committee for the International Consensus Conference on Concussion in Sport. He is a fellow of the American College of Sports Medicine, the Faculty of Sports & Exercise Medicine (UK) and the International Sports Medicine Federation. Jon serves on the advisory board of the Sports Health and Safety Institute at the University of Washington, Seattle. Apart from sports concussion, he has an interest in the pediatric and aging athlete, joint disease, tendinopathy, and